Cardiovascular effects of melatonin receptor agonists

Expert Opinion on Investigational Drugs

Volumn 21, Issue 11, 2012, Pages 1661-1678

  Paulis, Ludovit ^a,b   Simko, Fedor ^c   Laudon, Moshe ^d  

^a Comenius University ^*  (Slovakia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

^d NEURIM PHARMACEUTICALS LTD   (Israel)

Author keywords

Agomelatine; Antioxidant; Blood pressure; Circadin; Hypertension; Melatonin receptor; Metabolic syndrome; Piromelatine; Ramelteon; Tasimelteon; TIK 301

Indexed keywords

1 METHYL 4 PHENYLPYRIDIN 1 IUM CHLORIDE; 2 IODOMELATONIN; 5 M CA NAT; 5 METHOXYCARBONYLAMINO N ACETYLTRYPTAMINE; AGOMELATINE; CALMODULIN; CALRETICULIN; CAPTOPRIL; CARDIOVASCULAR AGENT; HORMONE RECEPTOR STIMULATING AGENT; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; LY 156735; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR AGONIST; MELITO; MELITON; N [2 (2,3,7,8 TETRAHYDRO 1H FURO[2,3 G]INDOL 1 YL)ETHYL]ACETAMIDE; N[2 (2,3,7,8 TETRAHYDROFURO(2,3 G)INDOL 1 YL)ETHYL]ACETAMIDE; NEU P 11; NIFEDIPINE; PAROXETINE; PD 6735; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PIROMELATINE; PLACEBO; PROTEIN KINASE C; RAMELTEON; S 21634; SERTRALINE; SIMVASTATIN; SPIRONOLACTONE; TASIMELTEON; TIK 301; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ACUTE HEART INFARCTION; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR EFFECT; CHRONIC DISEASE; CHRONOBIOLOGY; CORONARY ARTERY DISEASE; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TOLERABILITY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HORMONE BLOOD LEVEL; HORMONE URINE LEVEL; HUMAN; HYPERTENSION; INSOMNIA; INSULIN RELEASE; LOW DRUG DOSE; MAJOR DEPRESSION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MOOD DISORDER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PINEALECTOMY; PLASMA HALF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; SINGLE DRUG DOSE; SLEEP DISORDER; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; DRUG DESIGN; HUMANS; MELATONIN; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2;

EID: 84867492240     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.714771     Document Type: Review

References (139)

1. Hardeland R. Melatonin: signaling mechanisms of a pleiotropic agent. Biofactors 2009;35:183-92
2. Summary of product characteristics, Circadin, Approved EMA, June 2007
3. Summary of product characteristics, Rozerem (ramelteon), FDA approved label 10.20.08 NDA 21-782, S-008, S-009, S-010
4. Summary of product characteristics, Thymanax, Approved EMA, February 2009
5. Hardeland R. Investigational melatonin receptor agonists. Expert Opin Investig Drugs 2010;19:747-64
6. Paulis L, Simko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res 2007;56(6):671-84
7. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res 2007;42:319-22
8. Zanoboni A, Forni A, Zanoboni-Muciaccia W, Zanussi C. Effect of pinealectomy on arterial blood pressure and food and water intake in the rat. J Endocrinol Invest 1978;1:125-30
9. Simko F, Pechanova O, Pelouch V, et al. Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril. J Hypertens 2010;28(Suppl 1):S13-18
10. Paulis L, Vazan R, Simko F, et al. Morphological alterations and NO-synthase expression in the heart after continuous light exposure of rats. Physiol Res 2007;56(Suppl 2):S71-6
11. Sahna E, Acet A, Ozer MK, Olmez E. Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. J Pineal Res 2002;33:234-8
12. Vazan R, Janega P, Hojna S, et al. The effect of continuous light exposure of rats on cardiac response to ischemia-reperfusion and NO-synthase activity. Physiol Res 2007;56(Suppl 2):S63-9
13. Cunnane SC, Manku MS, Oka M, Horrobin DF. Enhanced vascular reactivity to various vasoconstrictor agents following pinealectomy in the rat: role of melatonin. Can J Physiol Pharmacol 1980;58:287-93
14. Kurcer Z, Sahna E, Olmez E. Vascular reactivity to various vasoconstrictor agents and endothelium-dependent relaxations of rat thoracic aorta in the long-term period of pinealectomy. J Pharmacol Sci 2006;101:329-34
15. Prunet-Marcassus B, Desbazeille M, Bros A, et al. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology 2003;144:5347-52
16. Lima FB, Machado UF, Bartol I, et al. Pinealectomy causes glucose intolerance and decreases adipose cell responsiveness to insulin in rats. Am J Physiol 1998;275:E934-41
17. Zanquetta MM, Seraphim PM, Sumida DH, et al. Calorie restriction reduces pinealectomy-induced insulin resistance by improving GLUT4 gene expression and its translocation to the plasma membrane. J Pineal Res 2003;35:141-8
18. Forman JP, Curhan GC, Schernhammer ES. Urinary melatonin and risk of incident hypertension among young women. J Hypertens 2010;28:446-51
19. Escames G, Khaldy H, Leon J, et al. Changes in iNOS activity, oxidative stress and melatonin levels in hypertensive patients treated with lacidipine. J Hypertens 2004;22:629-35
20. Benova M, Herichova I, Stebelova K, et al. Effect of L-NAME-induced hypertension on melatonin receptors and melatonin levels in the pineal gland and the peripheral organs of rats. Hypertens Res 2009;32:242-7.2009
21. Jonas M, Garfinkel D, Zisapel N, et al. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 2003;12:19-24
22. Zeman M, Dulkova K, Bada V, Herichova I. Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile. Life Sci 2005;76:1795-803
23. Yano Y, Kario K. Nocturnal blood pressure, morning blood pressure surge, and cerebrovascular events. Curr Hypertens Rep 2012. [Epub ahead of print]
24. Brugger P, Marktl W, Herold M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 1995;345:1408
25. Sakotnik A, Liebmann PM, Stoschitzky K, et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J 1999;20:1314-17
26. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Reiter RJ. Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2006;97:1162-4
27. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, et al. Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction. Atherosclerosis 2008;199:73-8
28. Dominguez-Rodriguez A, Abreu-Gonzalez P, Arroyo-Ucar E, Reiter RJ. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. J Pineal Res 2012. [Epub ahead of print]
29. Yildiz M, Akdemir O. Assessment of the effects of physiological release of melatonin on arterial distensibility and blood pressure. Cardiol Young 2009;19:198-203
30. Tain YL, Huang LT, Lin IC, et al. Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. J Pineal Res 2010;49:390-8
31. Pechanova O, Zicha J, Paulis L, et al. The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol 2007;561:129-36
32. Deniz E, Sahna E, Aksulu HE. Nitric oxide synthase inhibition in rats: melatonin reduces blood pressure and ischemia/reperfusion-induced infarct size. Scan Cardiovasc J 2006;40:248-52
33. Paulis L, Pechanova O, Zicha J, et al. Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats. J Hypertens 2009;27(Suppl):S11-16
34. Holmes SW, Sugden D. Proceedings: the effect of melatonin on pinealectomy-induced hypertension in the rat. Br J Pharmacol 1976;56:360P-1P
35. Simko F, Pechanova O, Pelouch V, et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J Hypertens Suppl 2009;27:S5-S10
36. Arangino S, Cagnacci A, Angiolucci M, et al. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol 1999;83:1417-19
37. Cagnacci A, Arangino S, Angiolucci M, et al. Influences of melatonin administration on the circulation of women. Am J Physiol 1998;274:R335-8
38. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag 2011;7:577-84
39. Cavallo A, Daniels SR, Dolan LM, et al. Blood pressure response to melatonin in type 1 diabetes. Pediatr Diabetes 2004;5:26-31
40. Lusardi P, Preti P, Savino S, et al. Effect of bedtime melatonin ingestion on blood pressure of normotensive subjects. Blood Press Monit 1997;2:99-103
41. Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol 2000;49:423-7
42. Lemoine P, Wade AG, Katz A, et al. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. Integr Blood Press Control 2012;5:9-17
43. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62
44. Rechcinski T, Trzos E, Wierzbowska-Drabik K, et al. Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability. Hypertens Res 2010;33:56-61
45. Paulis L, Pechanova O, Zicha J, et al. Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension. J Pineal Res 2010;48:102-8
46. Ghosh G, De K, Maity S, et al. Melatonin protects against oxidative damage and restores expression of GLUT4 gene in the hyperthyroid rat heart. J Pineal Res 2007;42:71-82
47. Paulis L, Pechanova O, Zicha J, et al. Melatonin improves the restoration of endothelium-derived constricting factor signalling and inner diameter in the rat femoral artery after cessation of L-NAME treatment. J Hypertens 2010;28(Suppl 1):S19-24
48. Nduhirabandi F, du Toit EF, Lochner A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? Acta Physiol (Oxf) 2012. [Epub ahead of print]
49. Kozirog M, Poliwczak AR, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res 2011;50:261-6
50. Lagneux C, Joyeux M, Demenge P, et al. Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart. Life Sci 2000;66:503-9
51. Tan DX, Manchester LC, Reiter RJ, et al. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. J Pineal Res 1998;25:184-91
52. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, et al. A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. Contemp Clin Trials 2007;28:532-9
53. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Melatonin and cardioprotection in the acute myocardial infarction: a promising cardioprotective agent. Int J Cardiol 2012;158:309-10
54. Kennaway DJ, Voultsios A. Circadian rhythm of free melatonin in human plasma. J Clin Endocrinol Metab 1998;83:1013-15
55. Dollins AB, Lynch HJ, Wurtman RJ, et al. Effect of pharmacological daytime doses of melatonin on human mood and performance. Psychopharmacol (Berl) 1993;112:490-6
56. Waldhauser F, Waldhauser M, Lieberman HR, et al. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984;39:307-13
57. Pandi-Perumal SR, Srinivasan V, Poeggeler B, et al. Drug insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol 2007;3:221-8
58. Raynaud F, Mauviard F, Geoffriau M, et al. Plasma 6-hydroxymelatonin, 6-sulfatoxymelatonin and melatonin kinetics after melatonin administration to rats. Biol Signals 1993;2:358-66
59. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61
60. Gibbs FP, Vriend J. The half-life of melatonin elimination from rat plasma. Endocrinology 1981;109:1796-8
61. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005;27:101-10
62. Wang XF, Pang CS, Pang SF, Wong TM. Melatonin potentiates phenylephrine-stimulated intracellular Ca2+ transient in smooth muscle cell of large arteries of chick embryo. J Cardiovasc Pharmacol 2002;40:356-62
63. Mei YA, Lee PP, Wei H, et al. Melatonin and its analogs potentiate the nifedipine-sensitive high-voltage-activated calcium current in the chick embryonic heart cells. J Pineal Res 2001;30:13-21
64. Tamura EK, Silva CL, Markus RP. Melatonin inhibits endothelial nitric oxide production in vitro. J Pineal Res 2006;41:267-74
65. Jockers R, Petit L, Lacroix I, et al. Novel isoforms of Mel1c melatonin receptors modulating intracellular cyclic guanosine 3',5'-monophosphate levels. Mol Endocrinol 1997;11:1070-81
66. Viswanathan M, Laitinen JT, Saavedra JM. Differential expression of melatonin receptors in spontaneously hypertensive rats. Neuroendocrinology 1992;56:864-70
67. Antol?n I, Rodr?guez C, Sa?nz RM, et al. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FASEB J 1996;10:882-90
68. Tan DX, Manchester LC, Terron MP, et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007;42:28-42
69. Tan DX, Manchester LC, Terron MP, et al. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J Pineal Res 2007;43:317-20
70. Bromme HJ, Morke W, Peschke D, et al. Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. J Pineal Res 2000;29:201-8
71. Sewerynek E, Ortiz GG, Reiter RJ, et al. Lipopolysaccharide-induced DNA damage is greatly reduced in rats treated with the pineal hormone melatonin. Mol Cell Endocrinol 1996;117:183-8
72. Pieri C, Marra M, Moroni F, et al. Melatonin: a peroxyl radical scavenger more effective than vitamin. E Life Sci 1994;55:PL271-6
73. Noda Y, Mori A, Liburdy R, Packer L. Melatonin and its precursors scavenge nitric oxide. J Pineal Res 1999;27:159-63
74. Castagnino HE, Lago N, Centrella JM, et al. Cytoprotection by melatonin and growth hormone in early rat myocardial infarction as revealed by Feulgen DNA staining. Neuro Endocrinol Lett 2002;23:391-5
75. Jennings RB, Sebbag L, Schwartz LM, et al. Metabolism of preconditioned myocardium: effect of loss and reinstatement of cardioprotection. J Mol Cell Cardiol 2001;33:1571-88
76. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Melatonin and cardiovascular disease: myth or reality? Rev Esp Cardiol 2012;65:215-18
77. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, et al. Elevated levels of oxidized low-density lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction. Atherosclerosis 2005;180:101-5
78. Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, et al. Usefulness of intraplatelet melatonin levels to predict angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2010;106:1540-4
79. Spadoni G, Bedini A, Rivara S, Mor M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther 2011;17:733-41
80. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010;8:51
81. Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for shortand long-term response. Curr Med Res Opin 2011;27:87-98
82. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007;23:2597-605
83. Cardinali DP, Pagano ES, Scacchi Bernasconi PA, et al. Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin. Neuro Endocrinol Lett 2011;32:588-606
84. Pandi-Perumal SR, Srinivasan V, Spence DW, et al. Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther 2009;26:613-26
85. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005;48:301-10
86. Hardeland R. Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci 2008;65:2001-18
87. Neubauer DN. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr Dis Treat 2008;4:69-79
88. Kohsaka M, Kanemura T, Taniguchi M, et al. Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia. Expert Rev Neurother 2011;11:1389-97
89. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat 2009;5:341-54
90. Srinivasan V, Pandi-Perumal SR, Trahkt I, et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci 2009;119:821-46
91. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64
92. Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother 2011;12:2411-19
93. Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother 2008;42:1822-31
94. Sansone RA, Sansone LA. Agomelatine: a novel antidepressant. Innov Clin Neurosci 2011;8:10-14
95. Kasper S, Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry 2009;10:117-26
96. Dubovsky SL, Warren C. Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin Investig Drugs 2009;18:1533-40
97. Ghosh A, Hellewell JS. A review of the efficacy and tolerability of agomelatine in the treatment of major depression. Expert Opin Investig Drugs 2007;16:1999-2004
98. Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf 2011;34:709-31
99. Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009;373:482-91
100. Cardinali DP, Cano P, Jimenez-Ortega V, Esquifino AI. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. Neuroendocrinology 2011;93:133-42
101. Lankford DA. Tasimelteon for insomnia. Expert Opin Investig Drugs 2011;20:987-93
102. Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr Opin Investig Drugs 2009;10:691-701
103. Rivara S, Mor M, Bedini A, et al. Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem 2008;8:954-68
104. Zemlan FP, Mulchahey JJ, Scharf MB, et al. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005;66:384-90
105. Mulchahey JJ, Goldwater DR, Zemlan FP. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. Life Sci 2004;75:1843-56
106. Tian SW, Laudon M, Han L, et al. Antidepressant-and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacol Sin 2010;31:775-83
107. She M, Deng X, Guo Z, et al. Neu-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol Res 2009;59:248-53
108. Yalkinoglu O, Zisapel N, Nir T, et al. Study of the safety, tolerability, pharmacokinetics and sleep promoting activity of Neu-P11, a novel putative insomnia drug in healthy humans. Sleep 2010;33:A220
109. Krause DN, Barrios VE, Duckles SP. Melatonin receptors mediate potentiation of contractile responses to adrenergic nerve stimulation in rat caudal artery. Eur J Pharmacol 1995;276:207-13
110. Lew MJ, Flanders S. Mechanisms of melatonin-induced vasoconstriction in the rat tail artery: a paradigm of weak vasoconstriction. Br J Pharmacol 1999;126:1408-18
111. Bucher B, Gauer F, Pevet P, Masson-Pevet M. Vasoconstrictor effects of various melatonin analogs on the rat tail artery in the presence of phenylephrine. J Cardiovasc Pharmacol 1999;33:316-22
112. Tailleux A, Torpier G, Bonnefont-Rousselot D, et al. Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta. Biochem Biophys Res Commun 2002;293:1114-23
113. Javaheri S. Sleep dysfunction in heart failure. Curr Treat Options Neurol 2008;10:323-35
114. Girotti L, Lago M, Ianovsky O, et al. Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease. J Pineal Res 2000;29:138-42
115. Altun A, Yaprak M, Aktoz M, et al. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci Lett 2002;327:143-5
116. Dominguez-Rodriguez A, Abreu-Gonzalez P, Sanchez-Sanchez JJ, et al. Melatonin and circadian biology in human cardiovascular disease. J Pineal Res 2010;49:14-22
117. Ruger M, Scheer FA. Effects of circadian disruption on the cardiometabolic system. Rev Endocr Metab Disord 2009;10:245-60
118. Reiter RJ, Tan DX, Korkmaz A, Ma S. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. Ann Med 2011. [Epub ahead of print]
119. Ting KN, Dunn WR, Davies DJ, et al. Studies on the vasoconstrictor action of melatonin and putative melatonin receptor ligands in the tail artery of juvenile Wistar rats. Br J Pharmacol 1997;122:1299-306
120. Tunstall RR, Shukla P, Grazul-Bilska A, et al. MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries. J Pharmacol Exp Ther 2011;336:127-33
121. O'Rourke ST, Hammad H, Delagrange P, et al. Melatonin inhibits nitrate tolerance in isolated coronary arteries. Br J Pharmacol 2003;139:1326-32
122. Anwar MM, Meki AR, Rahma HH. Inhibitory effects of melatonin on vascular reactivity: possible role of vasoactive mediators. Comp Biochem Physiol C Toxicol Pharmacol 2001;130:357-67
123. Masana MI, Doolen S, Ersahin C, et al. MT(2) melatonin receptors are present and functional in rat caudal artery. J Pharmacol Exp Ther 2002;302:1295-302
124. Girouard H, de Champlain J. Inhibitory effect of melatonin on alpha1-adrenergic-induced vasoconstriction in mesenteric beds of spontaneously hypertensive rats. Am J Hypertens 2004;17:339-46
125. Wu L, Wang R, de Champlain J. Enhanced inhibition by melatonin of alpha-adrenoceptor-induced aortic contraction and inositol phosphate production in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 1998;16:339-47
126. Garfinkel D, Zorin M, Wainstein J, et al. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes 2011;4:307-13
127. Grossman E, Laudon M, Yalcin R, et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med 2006;119:898-902
128. Oxenkrug GF, Summergrad P. Ramelteon attenuates age-associated hypertension and weight gain in spontaneously hypertensive rats. Ann NY Acad Sci 2010;1199:114-20
129. Leibowitz A, Peleg E, Sharabi Y, et al. The role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome. Am J Hypertens 2008;21:348-51
130. Kario K. Are melatonin and its receptor agonist specific antihypertensive modulators of resistant hypertension caused by disrupted circadian rhythm? J Am Soc Hypertens 2011;5:354-558
131. Lotufo CM, Lopes C, Dubocovich ML, et al. Melatonin and N-acetylserotonin inhibit leukocyte rolling and adhesion to rat microcirculation. Eur J Pharmacol 2001;430:351-7
132. Borba CP, Fan X, Copeland PM, et al. Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. J Clin Psychopharmacol 2011;31:653-8
133. Yin W, Hou H, Laudon M. Neu-P11, a novel melatonin agonist: effect on glucose transport in a cellular model ofinsulin resistance. Sleep 2008;31(Suppl):A26
134. Laudon M, She M, Deng X, et al. Neu-P11, a novel melatonin agonists inhibits weight gain and improves metabolic profiles in high-fat/high-sucrose- fed rats. Sleep 2009;32(Suppl):A39
135. Scheer FA, Van Montfrans GA, Van Someren EJ, et al. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004;43:192-7
136. Buijs RM, Van Eden CG, Goncharuk VD, Kalsbeek A. The biological clock tunes the organs of the body: timing by hormones and the autonomic nervous system. J Endocrinol 2003;177:17-26
137. Witte K, Schnecko A, Buijs RM, et al. Effects of SCN lesions on circadian blood pressure rhythm in normotensive and transgenic hypertensive rats. Chronobiol Int 1998;15:135-45
138. Xia CM, Shao CH, Xin L, et al. Effects of melatonin on blood pressure in stress-induced hypertension in rats. Clin Exp Pharmacol Physiol 2008;35:1258-64
139. Li HL, Kang YM, Yu L, et al. Melatonin reduces blood pressure in rats with stress-induced hypertension via GABAA receptors. Clin Exp Pharmacol Physiol 2009;36:436-40